Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on February 23, 2016. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401(K) plan. The transaction price was $38.64 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific director and connected person transactions noted above.
Important Facts for Investors
- Transaction Date: February 23, 2016 (Notified on February 25, 2016).
- Transaction Price: $38.64 per ADS.
- Director Activity: Dr M M Slaoui received an increase of 51 ADSs.
- Connected Person Activity: Dr K Slaoui (Connected Person of Dr M M Slaoui) received an increase of 4 ADSs.
- Source of Change: Revaluation of the cash element within the GSK 401(K) plan.